YANTAI, China, April 8, 2025 /PRNewswire/ -- On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were presented...
Read More Details
Finally We wish PressBee provided you with enough information of ( Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis )
Also on site :
- Conquering Soccer and Arming Warlords
- Pope Leo XIV marks feast day as Vatican launches campaign to help erase its $57-68 million deficit
- Antigovernment protesters clash with riot police in Serbia